ViewPoints: Ionis unveils the next best thing in Huntington’s disease
Mizuho | FirstWord Pharma
Dermira set to end development of olumacostat glasaretil after failure of two late-stage acne studies
Mizuho | FirstWord Pharma
Tech Today: Nasdaq Down 1%, Pondering VMware, Handicapping Broadcom
Mizuho | Barron's
Shares of virtualization pioneer VMware (VMW) are down $7.64, or 6%, at $116.02, despite the company yesterday afternoon beating fiscal Q4 expectations, and affirming its outlook: as William Blair’s Jason Ader writes, it was a “strong” report, but it doesn’t really matter. “VMware stock has now become event-driven,” with Michael Dell’s rumored interest in conducting a reverse merger. “The strong current fundamentals matter less,” he concludes.
Moscow Exchange Expands Access to its FX Market for International Investors
Broadway Technology | MondoVisione
Allergan Tanks to 5-Year Low as Botox Rivalry Heats with Mylan
Mizuho I Investor's Business Daily
Allergan (AGN) tanked to a five-year low Thursday after Mylan (MYL) and Revance Therapeutics (RVNC) announced their plan to bring a Botox copycat to the market just as U.S. regulators imposed a delay on an Allergan drug.